Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05564169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Masitinib in Patients With Mild Alzheimer's Disease

StatusNot Yet Recruiting
PhasePhase 3
SponsorAB Science
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2026 to Dec 2028 Start date: Jan 2024 to Jun 2026 · Primary endpoints: 2 to 1 · Completion date: Dec 2026 to Dec 2029 · 3 morev4 Show 6 more changesShow less
    • Start date: Jan 2024 to Jun 2026
    • Primary endpoints: 2 to 1
    • Completion date: Dec 2026 to Dec 2029
    • Eligibility criteria expanded, about 81 words
    • Secondary endpoints: 6 to 10
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Nov 15, 2025 to Dec 2026 Start date: Dec 15, 2022 to Jan 2024 · Trial status: Recruiting to Not Yet Recruiting · Completion date: Dec 15, 2025 to Dec 2026 · 2 morev3 Show 5 more changesShow less
    • Start date: Dec 15, 2022 to Jan 2024
    • Trial status: Recruiting to Not Yet Recruiting
    • Completion date: Dec 15, 2025 to Dec 2026
    • Site details revised at 9 of 9 sites
    • Publications: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 9 · Start date changed from estimate of Nov 15, 2022 to Dec 15, 2022v2 Show 2 more changesShow less
    • Study sites: 1 to 9
    • Start date changed from estimate of Nov 15, 2022 to Dec 15, 2022
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.
Trial Details
NCT Number NCT05564169
Lead Sponsor AB Science
Conditions Alzheimer Disease
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov